Implications of Cannabis Legalization for the US Federal Budget
Federal legislation to legalize, regulate, and tax cannabis could have significant impacts on the federal budget.
New MGA White Paper Examines Consequences of Regulatory Uncertainty for Employee Ownership
In a new white paper, Alex Brill details the consequences of regulatory uncertainty for businesses and provides a close look at the ongoing uncertainty facing companies owned by ESOPs.
MGA Releases White Paper on Role of PBMs in US Drug Pricing Debate
MGA latest white paper, by CEO Alex Brill, looks at the role of pharmacy benefit managers (PBMs) in the US prescription drug market.
MGA’s Latest: A Look at Community Health Centers
MGA’s state-by-state analysis of Community Health Centers’ economic impact.
MGA’s Latest Work Examining Digital Health Tools
MGA has released a new report today for the Coalition for Affordable Prescription Drugs (CAPD), “Patent Thickets and Lost Drug Savings.”
New MGA Analysis of the Adalimumab Biosimilars Market in the United States
The Biosimilars Council released the following statement in response to the new MGA report authored by Alex Brill and Christy Robinson.
- Patent Thicket Remedies
- Don’t Mix US Tax Administration Policy with the Israel-Hamas Conflict
- The Economics of “Delinking” PBM Compensation
- The Supreme Court Should Leave the Tax Code Alone
- Implications of Cannabis Legalization for the US Federal Budget
- Amicus Brief in Moore v. United States
- Biosimilars – Keys to Success in the Pharmacy Benefit
- New MGA White Paper Examines Consequences of Regulatory Uncertainty for Employee Ownership
- MGA Releases White Paper on Role of PBMs in US Drug Pricing Debate
- Unintended Consequences of Limiting PBMs
